SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : YMI: YM Biosciences, Inc. (YMI on AMEX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: John McCarthy9/19/2009 12:18:49 AM
   of 66
 
Severe radiation dermatitis with concurrent cetuximab and radiation — There is accumulating evidence that the administration of cetuximab and other EGFR inhibitors concurrent with radiation therapy increases the risk of potentially severe radiation dermatitis, rash, and mucositis [24,25]. (See "Concurrent chemoradiation for locoregionally advanced head and neck cancer", section on Complications and supportive care).

uptodate.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News